Designing Drugs that Target Specific G Protein Types
Author Information
Author(s): Slosky Lauren, Moore Madelyn, Person Kelsey, Alwin Abigail, Krusemark Campbell, Foster Noah, Ray Caroline, Inoue Asuka, Jackson Michael, Sheedlo Michael, Barak Lawrence, de Velasco Ezequiel Marron Fernandez, Olson Steven
Hypothesis
Can small molecules be designed to selectively activate specific G protein subtypes in GPCRs?
Conclusion
The study shows that small changes to a drug's structure can change which G protein subtype it activates, offering a new way to design safer and more effective medications.
Supporting Evidence
- The compound SBI-553 can switch the G protein preference of NTSR1.
- SBI-553 acts as both a molecular bumper and glue to change G protein coupling.
- Minor modifications to SBI-553 create allosteric modulators with different selectivity profiles.
- Selectivity profiles are consistent across different species.
- The findings suggest a new strategy for drug discovery targeting GPCRs.
Takeaway
Scientists found a way to make drugs that can choose which helper proteins they work with, which could make medicines better and safer.
Methodology
The study used the neurotensin receptor 1 (NTSR1) to explore how small molecules can change G protein coupling through specific mechanisms.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website